Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.

[1]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[2]  N. Normanno,et al.  Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. , 2021, JAMA oncology.

[3]  N. Djouder,et al.  When dormancy fuels tumour relapse , 2021, Communications biology.

[4]  V. Torri,et al.  Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. , 2021 .

[5]  A. Chella,et al.  Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. , 2021, Pharmacological research.

[6]  P. Jänne,et al.  Overcoming therapy resistance in EGFR-mutant lung cancer , 2021, Nature Cancer.

[7]  R. Mathijssen,et al.  Cross-resistance and drug sequence in prostate cancer. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  R. Danesi,et al.  Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy , 2021, Cancers.

[9]  M. Pichler,et al.  Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer , 2021, Cancers.

[10]  V. Conteduca,et al.  Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide , 2021, Prostate cancer and prostatic diseases.

[11]  Jinming Yu,et al.  Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors , 2020, Frontiers in Oncology.

[12]  A. Chella,et al.  Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer , 2020, Frontiers in Oncology.

[13]  M. Ahn,et al.  Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  C. Porta,et al.  A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC , 2020, Cancer Immunology, Immunotherapy.

[15]  R. Danesi,et al.  PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. , 2020, Pharmacological research.

[16]  L. Spaggiari,et al.  Understanding EGFR heterogeneity in lung cancer , 2020, ESMO Open.

[17]  R. Danesi,et al.  CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone , 2020, Cancer Chemotherapy and Pharmacology.

[18]  F. Boccardo,et al.  BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications , 2020, Journal of oncology.

[19]  A. Chella,et al.  erbB in NSCLC as a molecular target: current evidences and future directions , 2020, ESMO Open.

[20]  David C. Smith,et al.  TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC). , 2020 .

[21]  F. Ciardiello,et al.  Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? , 2020, Cancer treatment reviews.

[22]  C. Arteaga,et al.  Overcoming Endocrine Resistance in Breast Cancer. , 2020, Cancer cell.

[23]  D. Mukherji,et al.  Resistance Mechanisms to Anti-angiogenic Therapies in Cancer , 2020, Frontiers in Oncology.

[24]  L. Sequist,et al.  Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. , 2020, The Lancet. Oncology.

[25]  T. Assi,et al.  Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report. , 2019, Anti-cancer drugs.

[26]  E. Yoon,et al.  NFATC4 Promotes Quiescence and Chemotherapy Resistance in Ovarian Cancer , 2019, bioRxiv.

[27]  A. Chella,et al.  Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. , 2019, Clinical lung cancer.

[28]  I. Bièche,et al.  Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial , 2019, Annals of Oncology.

[29]  S. V. Estévez,et al.  Implications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza) , 2019, Annals of Oncology.

[30]  C. Porta,et al.  Androgen receptor (AR) splice variant 7 and full‐length AR expression is associated with clinical outcome: a translational study in patients with castrate‐resistant prostate cancer , 2019, BJU international.

[31]  Anyue Yin,et al.  A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors , 2019, CPT: pharmacometrics & systems pharmacology.

[32]  C. Porta,et al.  Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy , 2019, International journal of molecular sciences.

[33]  R. DiPaola,et al.  New developments in mechanisms of prostate cancer progression. , 2019, Seminars in cancer biology.

[34]  R. Danesi,et al.  Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients , 2019, Breast Cancer Research and Treatment.

[35]  N. Agarwal,et al.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.

[36]  Jianbo He,et al.  Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells. , 2019, Cell stem cell.

[37]  J. Hainsworth,et al.  Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. , 2019, The Lancet. Oncology.

[38]  Jiang Li,et al.  First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis , 2019, BMC cancer.

[39]  T. Yamasaki,et al.  Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer , 2019, Scientific Reports.

[40]  R. Danesi,et al.  Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial , 2019, JAMA oncology.

[41]  A. Turnbull,et al.  The evolving role of receptors as predictive biomarkers for metastatic breast cancer , 2018, Expert review of anticancer therapy.

[42]  E. Neri,et al.  Radiomics and liquid biopsy in oncology: the holons of systems medicine , 2018, Insights into Imaging.

[43]  Chunjiao Song,et al.  Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis , 2018, Cancer Cell International.

[44]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  Dirk Schadendorf,et al.  Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[46]  J. Barrett,et al.  Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  J. Tabernero,et al.  TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence , 2018, The Journal of clinical investigation.

[48]  D. Davar,et al.  MEK inhibitors for the treatment of NRAS mutant melanoma , 2018, Drug design, development and therapy.

[49]  F. de Marinis,et al.  Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non‐Small Cell Lung Cancer: The Role of Cancer Stem Cells , 2018, Stem cells.

[50]  R. Danesi,et al.  Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. , 2018, Critical reviews in oncology/hematology.

[51]  A. Giordano,et al.  Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors , 2018, Current opinion in pharmacology.

[52]  A. Bode,et al.  Recent advances in precision oncology research , 2018, npj Precision Oncology.

[53]  M. Gottesman,et al.  Revisiting the role of ABC transporters in multidrug-resistant cancer , 2018, Nature Reviews Cancer.

[54]  A. Bardelli,et al.  Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  S. Chandarlapaty,et al.  ESR1 and endocrine therapy resistance: more than just mutations. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Yong He,et al.  Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. , 2018, Lung cancer.

[57]  M. Koehler,et al.  Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer , 2018, Nature Communications.

[58]  F. Ciardiello,et al.  Role and targeting of anaplastic lymphoma kinase in cancer , 2018, Molecular Cancer.

[59]  R. Danesi,et al.  : Chronic Myeloid Leukemia : Stem Cell Niche and Response to Pharmacologic Treatment , 2018 .

[60]  L. Zender,et al.  Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics , 2018, Nature Reviews Gastroenterology & Hepatology.

[61]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[62]  H. Groen,et al.  Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers , 2018, Cancers.

[63]  T. Bihani,et al.  Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. , 2017, Pharmacology & therapeutics.

[64]  S. Sleijfer,et al.  Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients , 2017, Molecular oncology.

[65]  R. Dummer,et al.  Development of encorafenib for BRAF-mutated advanced melanoma , 2017, Current opinion in oncology.

[66]  C. Paweletz,et al.  OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms , 2017 .

[67]  Wiktor Paskal,et al.  Intratumor and Intertumor Heterogeneity in Melanoma , 2017, Translational oncology.

[68]  H. Scher,et al.  Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  N. Normanno,et al.  Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. , 2017, Molecular and clinical oncology.

[70]  C. Wellbrock,et al.  Overcoming resistance to BRAF inhibitors. , 2017, Annals of translational medicine.

[71]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[72]  C. Azzoli,et al.  MET amplification (amp) as a resistance mechanism to osimertinib. , 2017 .

[73]  J. Utikal,et al.  Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  W. Gradishar,et al.  Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer. , 2017, The oncologist.

[75]  S. Digumarthy,et al.  Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. , 2017, International journal of radiation oncology, biology, physics.

[76]  K. Pienta,et al.  Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Patrick Soon-Shiong,et al.  Molecular heterogeneity in breast cancer: State of the science and implications for patient care. , 2017, Seminars in cell & developmental biology.

[78]  G. Jenster,et al.  The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. , 2017, European urology.

[79]  C. Garbe,et al.  The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. , 2017, European journal of cancer.

[80]  A. Shaw,et al.  Targeting ALK: Precision Medicine Takes on Drug Resistance. , 2017, Cancer discovery.

[81]  Adam D. DePriest,et al.  Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. , 2017, European urology.

[82]  Lu Wang,et al.  Mechanisms of resistance to anti-EGFR therapy in colorectal cancer , 2016, Oncotarget.

[83]  A. Bardelli,et al.  Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer , 2016, Nature Communications.

[84]  Yi-long Wu,et al.  Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation , 2016, Thoracic cancer.

[85]  T. Betsuyaku,et al.  Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer , 2016, Molecular Cancer Research.

[86]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[87]  G. Hortobagyi,et al.  Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. , 2016, JAMA oncology.

[88]  M. Dowsett,et al.  Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  A. Bardelli,et al.  D01*Final Results of the HERACLES trial in HER2 amplified colorectal cancer , 2016 .

[90]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[91]  V. Torri,et al.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[92]  Benjamin Solomon,et al.  Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). , 2016 .

[93]  F. Meric-Bernstam,et al.  HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. , 2016 .

[94]  G. Hampton,et al.  Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant , 2016, Nature Communications.

[95]  A. Bardelli,et al.  The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer , 2016, Clinical Cancer Research.

[96]  Yih-Leong Chang,et al.  The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients , 2016, Oncotarget.

[97]  A. Cerone,et al.  Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. , 2016, Journal of theoretical biology.

[98]  E. Vasile,et al.  Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA , 2016, Oncotarget.

[99]  G. Getz,et al.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. , 2016, The New England journal of medicine.

[100]  C. Berking,et al.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. , 2015, European journal of cancer.

[101]  M. Dowsett,et al.  Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer , 2015, Science Translational Medicine.

[102]  D. Lin,et al.  Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  Delila Gasi Tandefelt,et al.  Plasma AR and abiraterone-resistant prostate cancer , 2015, Science Translational Medicine.

[104]  R. Schiff,et al.  The changing role of ER in endocrine resistance. , 2015, Breast.

[105]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[106]  R. Schiff,et al.  ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer , 2015, Nature Reviews Clinical Oncology.

[107]  R. Scharpf,et al.  The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.

[108]  Antoni Ribas,et al.  Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance , 2015, Cell.

[109]  V. Torri,et al.  Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas , 2015, Clinical Cancer Research.

[110]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[111]  Ron Bose,et al.  HER2 activating mutations are targets for colorectal cancer treatment. , 2015, Cancer discovery.

[112]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[113]  S. Vowler,et al.  Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study , 2015, EBioMedicine.

[114]  D. Adams,et al.  Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts , 2015, EMBO molecular medicine.

[115]  Jochen K. Lennerz,et al.  Detecting predictive androgen receptor modifications in circulating prostate cancer cells , 2015, Oncotarget.

[116]  D. Amadori,et al.  Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone , 2015, British Journal of Cancer.

[117]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[118]  S. Gabriel,et al.  A functional landscape of resistance to ALK inhibition in lung cancer. , 2015, Cancer cell.

[119]  K. Okuno,et al.  Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. , 2015, International journal of oncology.

[120]  J. Larkin,et al.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.

[121]  P. Angenendt,et al.  Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[122]  M. Salido,et al.  Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer , 2015, Clinical Cancer Research.

[123]  M. Herlyn,et al.  BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth , 2015, Clinical Cancer Research.

[124]  N. Hayward,et al.  Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma , 2014, Nature Communications.

[125]  Y. Ichinose,et al.  Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[126]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[127]  H. Bai,et al.  Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer. , 2014, Molecular and clinical oncology.

[128]  A. Bardelli,et al.  Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.

[129]  Paola Ghiorzo,et al.  Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma , 2014, Oncotarget.

[130]  A. Iafrate,et al.  Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib , 2014, Clinical Cancer Research.

[131]  William Pao,et al.  Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer , 2014, Nature Medicine.

[132]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[133]  N. Hayward,et al.  Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors , 2014, Nature Communications.

[134]  D. Hsiang,et al.  Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[135]  Makoto Nishio,et al.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. , 2014, Cancer discovery.

[136]  L. Crinò,et al.  Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[138]  Toyokawa Gouji,et al.  Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[139]  E. Oikonomou,et al.  Tumor Heterogeneity Revealed by KRAS, BRAF, and PIK3CA Pyrosequencing: KRAS and PIK3CA Intratumor Mutation Profile Differences and Their Therapeutic Implications , 2014, Human mutation.

[140]  Peter Ulz,et al.  Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing , 2014, PLoS genetics.

[141]  A. Bardelli,et al.  Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.

[142]  G. Pupo,et al.  BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.

[143]  A. Bardelli,et al.  Somatic alterations as the basis for resistance to targeted therapies , 2014, The Journal of pathology.

[144]  R. Yelensky,et al.  D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. , 2013, Cancer research.

[145]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[146]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[147]  R. Mirzayans,et al.  Role of Therapy-Induced Cellular Senescence in Tumor Cells and its Modification in Radiotherapy: The Good, The Bad and The Ugly , 2013 .

[148]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[149]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[150]  Amy Brock,et al.  Non-Darwinian dynamics in therapy-induced cancer drug resistance , 2013, Nature Communications.

[151]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[152]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[153]  H. Rui,et al.  Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. , 2013, Cancer research.

[154]  Alastair J. King,et al.  Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. , 2013, ACS medicinal chemistry letters.

[155]  S. Hagan,et al.  Targeted therapies in colorectal cancer—an integrative view by PPPM , 2013, EPMA Journal.

[156]  W. Sellers,et al.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.

[157]  R. Nawroth,et al.  Rational indication for docetaxel rechallenge in metastatic castration‐resistant prostate cancer , 2012, BJU international.

[158]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[159]  Xueying Mao,et al.  The complexity of prostate cancer: genomic alterations and heterogeneity , 2012, Nature Reviews Urology.

[160]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[161]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[162]  Kazuko Sakai,et al.  Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[163]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[164]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth following chemotherapy , 2012, Nature.

[165]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[166]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[167]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[168]  J. Pagès,et al.  Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[169]  J. Sosman,et al.  Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. , 2012, Cancer discovery.

[170]  G. Morgan,et al.  The genetic architecture of multiple myeloma , 2012, Nature Reviews Cancer.

[171]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[172]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[173]  Sung-Liang Yu,et al.  Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  F. Bosch,et al.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.

[175]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[176]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[177]  M. Mazumdar,et al.  Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma , 2012, PloS one.

[178]  Wei Zheng,et al.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. , 2011, Cancer research.

[179]  P. Jänne,et al.  Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.

[180]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[181]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[182]  Renzo Boldorini,et al.  Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer , 2011, Clinical Cancer Research.

[183]  Carlo C. Maley,et al.  Solving the Puzzle of Metastasis: The Evolution of Cell Migration in Neoplasms , 2011, PloS one.

[184]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[185]  A. Gilmartin,et al.  Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). , 2011, ACS medicinal chemistry letters.

[186]  M. Ladanyi,et al.  Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.

[187]  Francesca Zappacosta,et al.  GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition , 2011, Clinical Cancer Research.

[188]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[189]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[190]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[191]  J. Grandis,et al.  Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma , 2010, Expert opinion on investigational drugs.

[192]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[193]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[194]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[195]  H. Ohtsuki,et al.  Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.

[196]  W. Sellers,et al.  MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.

[197]  S. Morrison,et al.  Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.

[198]  S. Krauss,et al.  Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma , 2009, Clinical & Experimental Metastasis.

[199]  Hannah H. Chang,et al.  Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours , 2009, Nature Reviews Genetics.

[200]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[201]  M. Meyerson,et al.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.

[202]  Kevin M. Bradley,et al.  Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer , 2008, Nature Genetics.

[203]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[204]  R. Schiff,et al.  The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm , 2007, Clinical Cancer Research.

[205]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[206]  J. Lyons,et al.  Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.

[207]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[208]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[209]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[210]  M. Cobleigh,et al.  Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[211]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[212]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[213]  K. Kinzler,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[214]  S. Sleijfer,et al.  ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. , 2017, Cancer treatment reviews.

[215]  Ksenija Asić.  Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies. , 2016, Critical reviews in oncology/hematology.

[216]  A. Benson,et al.  Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors. , 2016, Cancer journal.

[217]  M. Herlyn,et al.  Heterogeneity in Melanoma. , 2016, Cancer treatment and research.

[218]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[219]  Antoni Ribas,et al.  A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. , 2014, Cancer discovery.

[220]  R. Salazar,et al.  The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[221]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[222]  M. Belvin,et al.  PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts , 2012, Cancer Chemotherapy and Pharmacology.

[223]  J. Troge,et al.  Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.